News - Cardio-vascular, Chelsea Therapeutics


Popular Filters

US FDA further delays Chelsea's Northera


US biotech firm Chelsea Therapeutics (Nasdaq: CHTP) has received acknowledgment of its resubmitted New…

BiotechnologyCardio-vascularChelsea TherapeuticsNorth AmericaNortheraRegulation

Chelsea Therapeutics resubmits NDA for Northera to the US FDA


US biotech firm Chelsea Therapeutics (Nasdaq: CHTP) has resubmitted a New Drug Application to the US…

Cardio-vascularChelsea TherapeuticsNortheraPharmaceuticalRegulation

Chelsea Thera to re-file Northera NDA with existing data; Celgene share buyback


Chelsea Therapeutics International (Nasdaq: CHTP) saw its shares more than double to $1.61 in pre-market…

BiotechnologyCardio-vascularCelgeneChelsea TherapeuticsFinancialNorth AmericaNortheraRegulation

Chelsea Thera gets disappointing news from FDA on Northera


US biotech firm Chelsea Therapeutics International (Nasdaq: CHTP) shares tumbled in pre-market trading…

BiotechnologyCardio-vascularChelsea TherapeuticsNorth AmericaNortheraRare diseasesRegulation

Back to top